T-DXd has been approved for the treatment of metastatic HER2-positive or HER2-low breast cancer (BC), HER2-mutant non-small cell lung cancer (NSCLC), metastatic HER2-positive gastric/gastroesophageal junction cancer (GC/GEJC). Here, ERBB2 is linked to non-small cell lung carcinoma.